Both AP2A1 and AP2A2 were reported to confer resistance to erlotinib, an anti-cancer drug, in lung cancer cells [78]; interact with Shc, an SH2-containing proto-oncogene involved in growth factor signaling in mammalian cancer cells [79]; and function in hemopoietic stem cell development [80]. This evidence concerns the gene AP2A2 and cancer.